134 related articles for article (PubMed ID: 25138022)
1. Coadministrating luteolin minimizes the side effects of the aromatase inhibitor letrozole.
Li F; Wong TY; Lin SM; Chow S; Cheung WH; Chan FL; Chen S; Leung LK
J Pharmacol Exp Ther; 2014 Nov; 351(2):270-7. PubMed ID: 25138022
[TBL] [Abstract][Full Text] [Related]
2. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
3. The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Li F; Chow S; Cheung WH; Chan FL; Chen S; Leung LK
J Nutr Biochem; 2013 Jun; 24(6):1112-6. PubMed ID: 23238426
[TBL] [Abstract][Full Text] [Related]
4. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
5. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
6. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
[TBL] [Abstract][Full Text] [Related]
7. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
9. The citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.
Ye L; Chan FL; Chen S; Leung LK
J Nutr Biochem; 2012 Oct; 23(10):1230-7. PubMed ID: 22209285
[TBL] [Abstract][Full Text] [Related]
10. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
11. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Chen HY; Liu ZH
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Swami S; Krishnan AV; Wang JY; Jensen K; Peng L; Albertelli MA; Feldman D
Horm Cancer; 2011 Jun; 2(3):190-202. PubMed ID: 21686077
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Akli S; Bui T; Wingate H; Biernacka A; Moulder S; Tucker SL; Hunt KK; Keyomarsi K
Clin Cancer Res; 2010 Feb; 16(4):1179-90. PubMed ID: 20145171
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic observations in MCF-7 aromatase xenografts.
Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
18. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
19. Effects of letrozole on hippocampal and cortical catecholaminergic neurotransmitter levels, neural cell adhesion molecule expression and spatial learning and memory in female rats.
Aydin M; Yilmaz B; Alcin E; Nedzvetsky VS; Sahin Z; Tuzcu M
Neuroscience; 2008 Jan; 151(1):186-94. PubMed ID: 18061360
[TBL] [Abstract][Full Text] [Related]
20. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
